Which Team Is Closest To Pausing Biological Time?

EverLife Capital · Monday, November 9, 2026

Reply “yes” to this email so EverLife Capital reaches your main inbox, not Promotions.

Some donated organs go unused for a simple reason: they can’t reach a patient in time.

A San Francisco startup says it has raised more than $100 million to stop that clock: freeze organs, bank them, and bring them back working. Its long-term roadmap includes doing the same for a whole body, starting in animals.

The trick is glass, not ice. When tissue freezes the normal way, water forms sharp ice crystals that damage cells. The newer approach fills the organ with protective chemicals and cools it so the water turns into a smooth, glass-like solid instead of ice.

Then comes the hard part: warming it back up. Warm it too slowly or unevenly and ice can still form, or the organ can crack. Researchers at the University of Minnesota mix tiny iron particles into the organ, then use a magnetic field to heat them, so the organ warms evenly from the inside. In rats, kidneys stored at minus 150°C and rewarmed this way kept transplanted animals alive for the full 30-day study.

So who is closest to doing this for human organs, and what’s real versus hype? That’s what I’m digging into this week.

Read the full story: who’s racing to do this, and what each has shown →

Or test yourself first. Today, how long can a donor heart last outside the body before it must be transplanted? Tap your answer:

→ A) About 4 to 6 hours

→ B) About 3 days

→ C) About a week

Each answer opens the full story on our website: whether you were right, who’s closest, and what each company has actually shown.

One quick vote before you go. Your tap decides what I write next:

Eric

P.S. I’m writing a full deep dive on every serious company in freezing and organ banking. Early-bird readers get it for 50% off ($24.50 instead of $49). Join the early-bird list → No payment now. EverLife Capital sells this report.

EverLife Capital publishes general educational research, not personalized investment or medical advice, and nothing here is a recommendation to buy or sell any security. The companies mentioned are private. EverLife Capital sells the report mentioned above. No company covered paid for coverage, directly or indirectly. Early research and animal results may not lead to treatments for people. EverLife Capital is published by Consult US, LLC. Neither Eric Pemper nor Consult US, LLC holds positions in companies mentioned. Some research and summaries are prepared with AI assistance and reviewed before publication.